

1 **Title**

2 LZTR1 deficiency exerts high metastatic potential by enhancing sensitivity to EMT induction
3 and controlling KLHL12-mediated collagen secretion

4

5 **Author Names:** Taiki Abe^{1,4*}, Shin-ichiro Kanno², Tetsuya Niihori¹, Miho Terao³, Shuji
6 Takada³, Yoko Aoki^{1*}

7

8 **Affiliations**

9 ¹ Department of Medical Genetics, Tohoku University School of Medicine, Sendai, Japan

10 ² Division of Dynamic Proteome, Institute of Development, Aging, and Cancer, Tohoku
11 University, Sendai, Japan

12 ³ Department of Systems BioMedicine, National Research Institute for Child Health and
13 Development, Tokyo, Japan

14 ⁴ Lead contact

15

16 *Correspondence should be addressed to Taiki Abe, Ph.D. and Yoko Aoki, MD, Ph.D.

17 Department of Medical Genetics, Tohoku University School of Medicine, Sendai 980-8574,
18 Japan

19 Email: Taiki Abe, abet@med.tohoku.ac.jp; Yoko Aoki, aokiy@med.tohoku.ac.jp, Phone:
20 +81-22-717-8137, Fax: +81-22-717-8142


21

22 **This PDF file includes:** Supplementary Figures, and Supplementary Tables.


23

1 **Supplementary Figures**

Supplemental Figure S1



A549-KO (*LZTR1*: c.178_199del, p.C60fs)




3

4 **Supplementary Figure S1.**

5 Sequence analysis of parental cells (A549-WT) and A549-KO cells.

6

Supplemental Figure S2



3 **Supplementary Figure S2.**


4 HEK293 cells were transfected with HA-LZTR1 and indicated FLAG-KRAS plasmids and

5 RAS expression levels evaluated.


6

Supplemental Figure S3


A: 24 h after drug treatment



B: A549+siRNA-LZTR1+TGF-β1




C



1 (A) Cells were treated with TGF- β 1 for 24 h and stained with anti-N-cadherin (NCAD)
2 antibody (red), ActinGreen 488 (F-actin, green) and NucBlue Stain (nuclei, blue). Scale bar,
3 10 μ m. (B, C) A549 cell lines were transfected with 10 nM Control-siRNA, LZTR1-siRNA,
4 or RREB1-siRNA. Cells were treated 24 h later with 10 ng/ml TGF- β 1 for 24 h and the
5 expression levels of EMT marker proteins were evaluated by western blot or RT-qPCR.
6

Supplemental Figure S4



1 **2 Supplementary Figure S4.**

3 (A) HEK293 cells grown on 13 mm² glass coverslips (Matsunami Glass, Osaka, Japan) were

4 transfected with FLAG-LZTR1 and KLHL12-Myc plasmids. The fixed cells were incubated

5 in PBS containing 0.1% Triton X-100 for 10 minutes and incubated in BlockAid Blocking

6 solution (Thermo Fisher Scientific) for 1 h at room temperature. The coverslips were

7 incubated overnight at 4°C with primary antibodies diluted in Can Get Signal Immunostain

8 Immunoreaction Enhancer Solution (Toyobo), and further incubated with secondary

9 antibodies for 1 h at room temperature. The yellow arrows indicate representative locations

10 where LZTR1 and KLHL12 overlap. (B) SK-N-SH cells were transfected with 10 nM

11 Control-siRNA or LZTR1-siRNA. The expression levels of LZTR1, COL1A1, SEC31A, and

12 ACTB were evaluated 24 or 48 h after transfection by western blot. (C) HEK293 cells were

13 transfected with indicated plasmids and siRNAs. Cell extracts were subjected to in vivo

1 ubiquitination assay. (D) The influence of RIT1 expression on LZTR1-mediated
2 KLHL12/SEC31A modification was evaluated by in vivo ubiquitination assay using
3 denatured cell lysates and anti-HA mAb-Magnetic Beads. (E, and F) HEK293 cells were
4 transfected with the indicated expression plasmids, and the lysates were subjected to co-
5 immunoprecipitation assays using anti-FLAG M2 Magnetic Beads or anti-HA mAb-Magnetic
6 Beads. The immunoprecipitants were subjected to western blot analyses. (G) The influence of
7 KLHL12 on LZTR1-mediated RIT1 ubiquitination was evaluated by in vivo ubiquitination
8 assay using denatured cell lysates and anti-FLAG M2 Magnetic Beads.

9

Supplementary Table 1. Primers used for construct preparation.

Construct name/mutated position	Forward primer (5' to 3')	Reverse primer (5' to 3')
HA-LZTR1	TGGAACATCGTATGGGTACATGGTGAAG	GATTACGCTGGTGGAGGTGGATCAGCTGGACC
	GGCTCCTTCTTAAAG	GGGC
KLHL12	CACCATGGGAGGCATTATGGCCCC	CTTCTCGCGGAGAACAC
KLHL12-FLAG	gacatcgactacaaggatgacgatgacaagTAGTGAAAG	atgatcttataatcaccgtcatggcttttagtcCTTCTCGCGGAG
	GGTGGGCGCGCCGACCCAGCTTCTTG	AACACAAACACCAGCATC
SEC31A	CACCATGAAGTTAAAGGAAGTAGATCGT	GACACCCAGCTTATTGGCCTGGG
	ACAGCC	
FLAG-KRAS	GGTGGAGGTGGATCAATGACTGAATATA	CTTGTTCATCGTCGTCCCTGTAGTCCATGGTGAA
	AACTTGTGGTAGTTGG	GGGCTCCTTCTTAAAG
FLAG-KRAS-G12C	TGTGGCGTAGGCAAGAGTGCC	AGCTCCAACCTACCACAAGTTATATTCA
FLAG-KRAS-G12D	ATGGCGTAGGCAAGAGTGCCTTG	CAGCTCCAACCTACCACAAGTTATATTCA
FLAG-KRAS-G12S	AGTGGCGTAGGCAAGAGTGCCTTG	AGCTCCAACCTACCACAAGTTATATTCA
FLAG-KRAS-G12V	TTGGCGTAGGCAAGAGTGCCTTGACG	CAGCTCCAACCTACCACAAGTTATATTCA

FLAG-KRAS-G13D ACGTAGGCAAGAGTGCCTTGACGATAC CACCAGCTCCAAC TACCACAAG

FLAG-KRAS-G13S AGCGTAGGCAAGAGTGCCTTGACG ACCAGCTCCAAC TACCACAAG

Supplementary Table 2. Primers for RT-qPCR.

Genes	Forward primer (5' to 3')	Reverse primer (5' to 3')
18S rRNA	ACCGCGGTTCTATTTGTTG	AGTCGGCATCGTTATGGTC
<i>LZTR1</i>	GGTGGAGACAATGGGAAGACC	GTGGGGTCCCAGTGGTAAAG
<i>RREB1</i>	CCCGGCCGTTGCTCC	TCTCTGGTAGTACTCGTTGACA
<i>CDH1 (ECAD)</i>	TGAGCACGTGAAGAACAGCA	GGTATGGGGCGTTGTCATT
<i>CDH2 (NCAD)</i>	TCGAAGGATGTGCATGAAGGA	GCAGGGCTCACTGCTCTCATA
<i>SNAIL</i>	CTAGGCCCTGGCTGCTACAA	GACATCTGAGTGGGTCTGGAG
<i>SLUG</i>	CATGCCTGTCATACCACAAAC	GGTGTCAAGATGGAGGGAGGG
<i>ZEB1</i>	GACAGTGTACCAGGGAGGAG	ACTCGCATTCATCATCTTTACTGT
<i>ZO-1</i>	GTCCAGAACATCTCGGAAAAGTGCC	CTTCAGCGCACCATACCAACC
<i>VIM</i>	GCCGAAAACACCCTGCAATC	GCGTTCAAGGTCAAGACGTG
<i>CLDN1</i>	GGGCAGATCCAGTGCAAAGT	GAGGATGCCAACCACCATCA
<i>FNI</i>	CCCTGGTGTACAGAGGCTA	GTTGGGAAAGCTCGTCTGTC
<i>COL1AI</i>	GGCTCCTGCTCCTCTTAGC	GGTTTCCACACGTCTCGGTC